Adamax
Adamax (Semax-Adamax)
Overview
Adamax is a modified version of Semax in which the methionine residue is replaced with adamantylglycine — a modification designed to dramatically increase lipophilicity and blood-brain barrier penetration compared to standard Semax. It is considered one of the most potent Semax analogs available in research peptide markets with anecdotal reports of significantly stronger and longer-lasting cognitive effects than standard Semax at equivalent doses.
Mechanism of Action
Adamax shares Semax's core neurological mechanisms — BDNF and NGF upregulation dopaminergic and serotonergic modulation and neuroprotection — but the adamantyl modification creates a much more lipophilic molecule. Lipophilicity is a key determinant of blood-brain barrier penetration for peptides and the adamantyl group dramatically increases membrane permeability. This means a greater proportion of the administered dose reaches the central nervous system compared to standard Semax. The adamantyl group also confers resistance to enzymatic degradation. The result is a compound that reportedly produces Semax-like effects with greater intensity and duration though formal pharmacokinetic data in humans is not available.
Dosage Information
Typical Dose
100-300 mcg per dose
Frequency
Once daily in the morning
Administration
Intranasal spray
Notes
Very limited human safety and efficacy data. Start at lowest dose. The adamantyl modification is novel and long-term effects are unknown. Approach with appropriate caution.
Where does Adamax sit?
See how this peptide compares across all 111 peptides in our database.
Evidence Score
0.07
Potential Side Effects
Community Experiences
No experiences shared yet. Be the first!
Quick Facts
- Administration
- Intranasal spray
- Typical Dose
- 100-300 mcg per dose
- Frequency
- Once daily in the morning
- References
- 0 curated + 0 from PubMed
- Evidence Score
- 0.1 / 100